AbbVie Inc. Files 8-K Report

TL;DR

AbbVie filed an 8-K on 9/11/25 for financial disclosures.

AI Summary

On September 11, 2025, AbbVie Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific material events or financial figures beyond the filing date and company information were detailed in the provided text.

Why It Matters

This filing indicates AbbVie Inc. is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• AbbVie Inc. (company) — Filer of the 8-K report
• September 11, 2025 (date) — Date of the earliest event reported

FAQ

From the Filing

0001104659-25-089245.txt : 20250911 0001104659-25-089245.hdr.sgml : 20250911 20250911073054 ACCESSION NUMBER: 0001104659-25-089245 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250911 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250911 DATE AS OF CHANGE: 20250911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 251307221 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2525781d1_8k.htm FORM 8-K false 0001551152 0001551152 2025-09-11 2025-09-11 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-09-11 2025-09-11 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2025-09-11 2025-09-11 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2025-09-11 2025-09-11 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2025-09-11 2025-09-11 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2025-09-11 2025-09-11 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2025-09-11 2025-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 11, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange         NYSE Texas 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for c